Virologica Sinica

, Volume 30, Issue 4, pp 269–276 | Cite as

Development and characterization of a clinical strain of Coxsackievirus A16 and an eGFP infectious clone

  • Chenglin Deng
  • Xiaodan Li
  • Siqing Liu
  • Linlin Xu
  • Hanqing Ye
  • Cheng-Feng Qin
  • Bo Zhang
Research Article

Abstract

Coxsackievirus A16 (CA16) is one of the major causes of hand, foot, and mouth disease (HFMD) worldwide, which is a common illness that affects children. The frequent occurrence of HFMD outbreaks has become a serious public health problem in Asia. Therefore, it is important to understand the pathogenesis and replication of CA16. In this study, a stable infectious cDNA clone of an epidemic strain of Coxsackievirus A16 (CA16) was assembled, and subsequently a reporter virus (eGFP-CA16) was constructed by inserting the eGFP gene between the 5′-UTR and the N-terminus of VP4, with the addition of a 2A protease cleavage site (ITTLG) at its C-terminus. This was transfected into Vero cells to generate infectious recombinant viruses. The growth characteristics and plaque morphology, in vitro, in mammalian cells were found to be indistinguishable between the parental and recombinant viruses. Although the eGFP-CA16 showed smaller plaque size as compared to recombinant CA16, both were found to exhibit similar growth trends and EC50 of NITD008. In summary, this stable infectious cDNA clone should provide a valuable experimental system to study CA16 infection and host response. The eGFP-CA16 is expected to provide a powerful tool to monitor eGFP expression in infected cells and to evaluate the antiviral activity of potential antiviral agents in the treatment of CA16 infections.

Keywords

Coxsackievirus A16 (CA16) infectious cDNA clone reporter virus eGFP-CA16 antiviral drug discovery 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. 2013. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine, 31: 2215–2221.CrossRefPubMedGoogle Scholar
  2. Deng CL, Yeo H, Ye HQ, Liu SQ, Shang BD, Gong P, Alonso S, Shi PY, Zhang B. 2014. Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol, 88: 11915–11923.PubMedCentralCrossRefPubMedGoogle Scholar
  3. Goto K, Sanefuji M, Kusuhara K, Nishimura Y, Shimizu H, Kira R, Torisu H, Hara T. 2009. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis, 15: 1689–1691.PubMedCentralCrossRefPubMedGoogle Scholar
  4. Han JF, Yu N, Pan YX, He SJ, Xu LJ, Cao RY, Li YX, Zhu SY, Zhang Y, Qin ED, Che XY, Qin CF. 2014. Phenotypic and genomic characterization of human coxsackievirus A16 strains with distinct virulence in mice. Virus Res, 179: 212–219.CrossRefPubMedGoogle Scholar
  5. Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, Shiraki K, Kurata T, Takizawa T. 2009. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis, 62: 254–259.PubMedGoogle Scholar
  6. Li W, Yi L, Su J, Lu J, Zeng H, Guan D, Ma C, Zhang W, Xiao H, Li H, Zhang Y, Lin J, Ke C. 2013. Seroepidemiology of human enterovirus71 and coxsackievirusA16 among children in Guangdong province, China. BMC Infect Dis, 13: 322.PubMedCentralCrossRefPubMedGoogle Scholar
  7. Lim XF, Jia Q, Chow VTK, Kwang J. 2013. Characterization of a novel monoclonal antibody reactive against the N-terminal region of Enterovirus 71 VP1 capsid protein. J Virol Methods, 188: 76–82.CrossRefPubMedGoogle Scholar
  8. Man-Li T, Szyporta M, Fang LX, Kwang J. 2012. Identification and characterization of a monoclonal antibody recognizing the linear epitope RVADVI on VP1 protein of enterovirus 71. J Med Virol, 84: 1620–1627.CrossRefPubMedGoogle Scholar
  9. Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. 2012. A Neonatal Mouse Model of Coxsackievirus A16 for Vaccine Evaluation. J Virol, 86: 11967–11976.PubMedCentralCrossRefPubMedGoogle Scholar
  10. Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. 2013. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother, 10: 360–367.PubMedCentralCrossRefPubMedGoogle Scholar
  11. Oberste MS, Maher K, Kilpatrick DR, Pallansch MA. 1999. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol, 73: 1941–1948.PubMedCentralPubMedGoogle Scholar
  12. Perera D, Yusof MA, Podin Y, Ooi MH, Thao NT, Wong KK, Zaki A, Chua KB, Malik YA, Tu PV, Tien NT, Puthavathana P, Mc-Minn PC, Cardosa MJ. 2007. Molecular phylogeny of modern coxsackievirus A16. Arch Virol, 152: 1201–1208.CrossRefPubMedGoogle Scholar
  13. Poyry T, Hyypia T, Horsnell C, Kinnunen L, Hovi T, Stanway G. 1994. Molecular analysis of coxsackievirus A16 reveals a new genetic group of enteroviruses. Virology, 202: 982–987.CrossRefPubMedGoogle Scholar
  14. Puenpa J, Theamboonlers A, Korkong S, Linsuwanon P, Thongmee C, Chatproedprai S, Poovorawan Y. 2011. Molecular characterization and complete genome analysis of human enterovirus 71 and coxsackievirus A16 from children with hand, foot and mouth disease in Thailand during 2008–2011. Arch Virol, 156: 2007–2013.CrossRefPubMedGoogle Scholar
  15. Shang B, Deng C, Ye H, Xu W, Yuan Z, Shi PY, Zhang B. 2013. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antiviral Res, 97: 198–205.CrossRefPubMedGoogle Scholar
  16. Shi J, Huang X, Liu Q, Huang Z. 2013. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine, 31: 2130–2136.CrossRefPubMedGoogle Scholar
  17. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. 2004. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J, 23: 275–276.CrossRefPubMedGoogle Scholar
  18. Wei W, Guo H, Li J, Ren S, Wei Z, Bao W, Hu X, Zhao K, Zhang W, Zhou Y, Sun F, Markham R, Yu XF. 2014. Circulating HFMD-associated coxsackievirus A16 is genetically and phenotypically distinct from the prototype CV-A16. PLoS One, 9: e94746.PubMedCentralCrossRefPubMedGoogle Scholar
  19. Xu M, Su L, Cao L, Zhong H, Dong N, Xu J. 2013. Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: a molecular epidemiological analysis. BMC Infect Dis, 13: 489.PubMedCentralCrossRefPubMedGoogle Scholar
  20. Zhang CH, Ma WQ, Yang YL, Wang HM, Dong FT, Huang ZX. 2015. Median effective effect-site concentration of sufentanil for wake-up test in adolescents undergoing surgery: a randomized trial. BMC Anesthesiol, 15: 27.PubMedCentralCrossRefPubMedGoogle Scholar
  21. Zhang J, Dong M, Jiang B, Dai X, Meng J. 2012. Antigenic characteristics of the complete and truncated capsid protein VP1 of enterovirus 71. Virus Res, 167: 337–342.CrossRefPubMedGoogle Scholar
  22. Zhang Y, Wang D, Yan D, Zhu S, Liu J, Wang H, Zhao S, Yu D, Nan L, An J, Chen L, An H, Xu A, Xu W. 2010. Molecular evidence of persistent epidemic and evolution of subgenotype B1 coxsackievirus A16-associated hand, foot, and mouth disease in China. J Clin Microbiol, 48: 619–622.PubMedCentralCrossRefPubMedGoogle Scholar
  23. Zhou F, Kong F, Wang B, McPhie K, Gilbert GL, Dwyer DE. 2011. Molecular characterization of enterovirus 71 and coxsackievirus A16 using the 5′ untranslated region and VP1 region. J Med Microbiol, 60: 349–358.CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Chenglin Deng
    • 1
  • Xiaodan Li
    • 1
    • 2
  • Siqing Liu
    • 1
  • Linlin Xu
    • 1
    • 2
  • Hanqing Ye
    • 1
  • Cheng-Feng Qin
    • 3
  • Bo Zhang
    • 1
  1. 1.Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina
  2. 2.University of Chinese Academy of SciencesBeijingChina
  3. 3.State Key Laboratory of Pathogen and BiosecurityBeijing Institute of Microbiology and EpidemiologyBeijingChina

Personalised recommendations